343 related articles for article (PubMed ID: 22290080)
1. Inactivation of GPR30 reduces growth of triple-negative breast cancer cells: possible application in targeted therapy.
Girgert R; Emons G; Gründker C
Breast Cancer Res Treat; 2012 Jul; 134(1):199-205. PubMed ID: 22290080
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of GPR30 by estriol prevents growth stimulation of triple-negative breast cancer cells by 17β-estradiol.
Girgert R; Emons G; Gründker C
BMC Cancer; 2014 Dec; 14():935. PubMed ID: 25496649
[TBL] [Abstract][Full Text] [Related]
3. 17β-estradiol-induced growth of triple-negative breast cancer cells is prevented by the reduction of GPER expression after treatment with gefitinib.
Girgert R; Emons G; Gründker C
Oncol Rep; 2017 Feb; 37(2):1212-1218. PubMed ID: 27959426
[TBL] [Abstract][Full Text] [Related]
4. GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer.
Mo Z; Liu M; Yang F; Luo H; Li Z; Tu G; Yang G
Breast Cancer Res; 2013 Nov; 15(6):R114. PubMed ID: 24289103
[TBL] [Abstract][Full Text] [Related]
5. G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells.
Albanito L; Madeo A; Lappano R; Vivacqua A; Rago V; Carpino A; Oprea TI; Prossnitz ER; Musti AM; Andò S; Maggiolini M
Cancer Res; 2007 Feb; 67(4):1859-66. PubMed ID: 17308128
[TBL] [Abstract][Full Text] [Related]
6. The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells.
Vivacqua A; Bonofiglio D; Recchia AG; Musti AM; Picard D; Andò S; Maggiolini M
Mol Endocrinol; 2006 Mar; 20(3):631-46. PubMed ID: 16239258
[TBL] [Abstract][Full Text] [Related]
7. The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17beta-estradiol and phytoestrogens in breast cancer cells.
Maggiolini M; Vivacqua A; Fasanella G; Recchia AG; Sisci D; Pezzi V; Montanaro D; Musti AM; Picard D; Andò S
J Biol Chem; 2004 Jun; 279(26):27008-16. PubMed ID: 15090535
[TBL] [Abstract][Full Text] [Related]
8. Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines.
Fan P; McDaniel RE; Kim HR; Clagett D; Haddad B; Jordan VC
Eur J Cancer; 2012 Dec; 48(18):3488-98. PubMed ID: 22658320
[TBL] [Abstract][Full Text] [Related]
9. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF.
Filardo EJ; Quinn JA; Bland KI; Frackelton AR
Mol Endocrinol; 2000 Oct; 14(10):1649-60. PubMed ID: 11043579
[TBL] [Abstract][Full Text] [Related]
10. Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis.
Filardo EJ; Quinn JA; Frackelton AR; Bland KI
Mol Endocrinol; 2002 Jan; 16(1):70-84. PubMed ID: 11773440
[TBL] [Abstract][Full Text] [Related]
11. The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells.
Ariazi EA; Brailoiu E; Yerrum S; Shupp HA; Slifker MJ; Cunliffe HE; Black MA; Donato AL; Arterburn JB; Oprea TI; Prossnitz ER; Dun NJ; Jordan VC
Cancer Res; 2010 Feb; 70(3):1184-94. PubMed ID: 20086172
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of growth hormone receptor by Somavert reduces expression of GPER and prevents growth stimulation of triple-negative breast cancer by 17β-estradiol.
Girgert R; Emons G; Gründker C
Oncol Lett; 2018 Jun; 15(6):9559-9566. PubMed ID: 29805678
[TBL] [Abstract][Full Text] [Related]
13. 17beta-estradiol, genistein, and 4-hydroxytamoxifen induce the proliferation of thyroid cancer cells through the g protein-coupled receptor GPR30.
Vivacqua A; Bonofiglio D; Albanito L; Madeo A; Rago V; Carpino A; Musti AM; Picard D; Andò S; Maggiolini M
Mol Pharmacol; 2006 Oct; 70(4):1414-23. PubMed ID: 16835357
[TBL] [Abstract][Full Text] [Related]
14. GPER mediates enhanced cell viability and motility via non-genomic signaling induced by 17β-estradiol in triple-negative breast cancer cells.
Yu T; Liu M; Luo H; Wu C; Tang X; Tang S; Hu P; Yan Y; Wang Z; Tu G
J Steroid Biochem Mol Biol; 2014 Sep; 143():392-403. PubMed ID: 24874276
[TBL] [Abstract][Full Text] [Related]
15. Estradiol and tamoxifen induce cell migration through GPR30 and activation of focal adhesion kinase (FAK) in endometrial cancers with low or without nuclear estrogen receptor α (ERα).
Tsai CL; Wu HM; Lin CY; Lin YJ; Chao A; Wang TH; Hsueh S; Lai CH; Wang HS
PLoS One; 2013; 8(9):e72999. PubMed ID: 24039841
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor induces G protein-coupled receptor 30 expression in estrogen receptor-negative breast cancer cells.
Albanito L; Sisci D; Aquila S; Brunelli E; Vivacqua A; Madeo A; Lappano R; Pandey DP; Picard D; Mauro L; Andò S; Maggiolini M
Endocrinology; 2008 Aug; 149(8):3799-808. PubMed ID: 18467441
[TBL] [Abstract][Full Text] [Related]
17. Regulation of ERRalpha gene expression by estrogen receptor agonists and antagonists in SKBR3 breast cancer cells: differential molecular mechanisms mediated by g protein-coupled receptor GPR30/GPER-1.
Li Y; Birnbaumer L; Teng CT
Mol Endocrinol; 2010 May; 24(5):969-80. PubMed ID: 20211987
[TBL] [Abstract][Full Text] [Related]
18. mRNA expression of the type I growth factor receptors in the human breast cancer cells MCF-7: regulation by estradiol and tamoxifen.
Revillion F; Pawlowski V; Lhotellier V; Louchez MM; Peyrat JP
Anticancer Res; 2003; 23(2B):1455-60. PubMed ID: 12820409
[TBL] [Abstract][Full Text] [Related]
19. Interaction Between CCL18 and GPR30 Differs from the Interaction Between Estradiol and GPR30.
Schmidt-Wolf R; Zissel G
Anticancer Res; 2020 Jun; 40(6):3097-3108. PubMed ID: 32487604
[TBL] [Abstract][Full Text] [Related]
20. Calycosin inhibits the in vitro and in vivo growth of breast cancer cells through WDR7-7-GPR30 Signaling.
Tian J; Wang Y; Zhang X; Ren Q; Li R; Huang Y; Lu H; Chen J
J Exp Clin Cancer Res; 2017 Nov; 36(1):153. PubMed ID: 29096683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
